Abstract:One problem in blood group testing is that IgG monoclonal antibodies, in contrast to IgM, do not usually agglutinate erythrocytes. One of the reasons is the high zeta potential induced by the negative charge of the cell surface. During the last few years, we have produced a series of human monoclonal antibodies by the conventional fusion technique directed against antigens of the Rh blood group system. Some of these monoclonals, especially those directed against Rh-subgroups such as the c-antigen, were mainly of the IgG-subtype and unsuitable for agglutination tests. We have therefore tried to establish a molecular biological method to make IgM-like molecules from IgG monoclonals. From the c-antigen specific human hybridoma BS 240 (IgG subtype), we isolated mRNA that was transcribed into cDNA and then amplified by PCR using family specific primers. The heavy and light chain products were cloned into the pHen vector containing a DNA linker fragment, a myc-tag for identification and a His-tag for purification. After transformation in E.coli and phage rescue with helper phage, the culture supernatant was screened for antigen positive recombinant phage antibodies as a first control for specificity using c-antigen positive erythrocytes and anti-M13 antibodies as bridging antibodies (Coombs technique). Erythrocytes being negative for the c-antigen served as a negative control. After changing the culture conditions, soluble single chain fragments (scFv) were obtained from the periplasmatic extract. Specificity was shown using the c-antigen positive and negative erythrocytes and the 9E10 antibody (anti-myc) as a bridging antibody. To obtain IgM-like molecules, DNA coding for the specific scFv was cloned into the vector pSTE containing DNA coding for the monomer of core streptavidin. After expression, purification and refolding of the monomer, the core streptavidin combines to form tetrameric structures, termed scFv::strep, that are able to bind biotin as shown using ELISA plates coated with biotinylated BSA. Binding was detected with 9E10 and a peroxidase conjugated secondary antibody. In the agglutination assay, the construct was able to agglutinate c-antigen positive erythrocytes but not the negative erythrocytes. These experiments show that it is possible to construct IgM-like agglutinating molecules from cells containing secreting IgG antibodies. Experiments employing human antibody libraries instead of hybridoma cell lines are now in progress.

[Effect of IgG on the primary or secondary induced antibody synthesis]

Effects of Anchor Structure and Glycosylation of Fcγ Receptor III on Ligand Binding Affinity.

The mode of action of treatment by IgG of haemolytic anaemia induced by an anti-erythrocyte monoclonal antibody

Effects of N-glycans on the structure of human IgA2

The Ligands for Human IgG and Their Effector Functions

Binding of immunoglobulin classes and subclasses to human neutrophils and eosinophils

Impact of structural modifications of IgG antibodies on effector functions

IgG sialylation occurs in B cells pre antibody secretion

IgG in the control of FcεRI activation: a battle on multiple fronts

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities

Effect of Immunoregulation of IVIG to the Expression of Inhibitory Fc Receptor

Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1

Two mechanisms of transferrin receptor induction by anti-Ig in B cells.

From IgG monoclonals to IgM-like molecules

Influence of glycan modification on IgG1 biochemical and biophysical properties

Immunomodulatory and anti‐inflammatory properties of immunoglobulin G antibodies

IgA subclasses have different effector functions associated with distinct glycosylation profiles

Crystal Structure Of Sialylated Igg Fc: Implications For The Mechanism Of Intravenous Immunoglobulin Therapy

Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

Glycan-independent Binding and Internalization of Human IgM to FCMR, Its Cognate Cellular Receptor